

# ALLOMEDIN®

St. Petersburg  
2019 Year

# ALLOMEDIN®

Skincare cosmetic used for herpes



4g or 10g of transparent hydrogel

On the market since 2005

Declaration of conformity TR CU 009/2011

# ALLOMEDIN®

## COMPOSITION OF THE GEL :

- Water,
- Carbopol,
- Phenoxyethanol,
- Sodium Hydroxide,
- Allantoin,
- Ethylhexylglycerin,
- ALLOSTATIN-1

The substances included in the gel are safe and approved for use in cosmetology

Store in a refrigerator at a temperature of 2C to 8C+

Expiration date of 24 months

# ALLOMEDIN®

THE ACTIVE SUBSTANCE IS – ALLOSTATIN1®

Synthetic peptide exhibiting selective activity against  
natural human killer cells

## ALLOSTATIN1®


PROVIDES ANTI-VIRAL ACTION DUE TO  
CYTOTOXIC CELL ACTIVATION

## ALLOSTATIN1®


ACTIVATES RECOGNITION BY IMMUNE-  
COMPETENT CELLS OF PATHOLOGICALLY  
CHANGED SKIN CELLS

## ALLOSTATIN1®

LAUNCHES A CASCADE OF PROTECTIVE  
REACTIONS AIMED AT SURPRESSING VIRUS  
REPLICATION




# MECHANISM OF ACTION - ALLOMEDIN®



## RECURRENT HERPES VIRUS

---


In the infected cells, marked in green, the multiplication of viral particles begin.



## ACTION - EFFECT

---

Allomedin® stimulates the activity of cytotoxic cells (killer T cells and NK cells), which leads to apoptosis of infected cells.



## RESULT

---

No infected cells remain in the tissue – a long relapse-free period

## APPLICATION OF **ALLOMEDIN®** GEL


- The gel should be applied to the problematic area of the skin with a herpetic rash at every discomfort (itching, burning), and allowed to be absorbed.
- The gel is transparent, absorbs quickly, leaving no residue.
- Can be applied without a mirror under decorative cosmetics.
- Apply within 2-7 days, until the skin (mucous membrane) is completely restored
- The use of **ALLOMEDIN®** gel will help to increase the relapse-free period up to 4-6 months.
- The gel does not contain hormonal and s / d substances.
- Does not irritate and sensitize the skin.

# CLINICAL APPROBATION OF ALLOMEDIN® GEL

## Клиническая апробация препарата «Алломедин» проводилась в ведущих клиниках страны:

1. ФГУ «Нижегородский научно-исследовательский кожно-венерологический институт» Минздравсоцразвития России, 4 дерматовенерологическое отделение (г. Нижний Новгород).
2. ФГУ «Приволжский окружной медицинский центр» ФМБА России, поликлиника №3 (г. Нижний Новгород).
3. Первый Московский государственный медицинский университет им. И.М. Сеченова, клиника кожных и венерических болезней Университетской клинической больницы №2 (г. Москва).
4. Ставропольская государственная медицинская академия, кафедра дерматовенерологии и косметологии (клиника - ГУЗ «Краевой клинический кожно-венерологический диспансер») (г. Ставрополь).
5. 25 Центральный военно- клинический госпиталь РВСН
6. Кафедра дерматологии Санкт-Петербургской медицинской академии последипломного образования;
7. Республиканская клиническая инфекционная больница Федерального агентства по здравоохранению и социальному развитию. Санкт Петербург.
8. Кафедра дерматовенерологии СЗГМУ им .И.И. Мечникова
9. Научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» (г. Санкт-Петербург)

# An open comparative study of the efficacy and safety of ALLOMEDIN® gel in the prevention of recurrence of herpes simplex.



**Picture 1**

Relief of pruritus in patients receiving topical therapy for recurrent herpes simplex (points).

**Picture 2**

Relief of burning sensation in patients receiving topical therapy for recurrent herpes simplex (points).

**DIGITAL  
Picture 3**


Pain relief in patients receiving topical therapy for recurrent herpes simplex (points).

**SEO & GOOGLE  
Picture 4**


Reduction of hyperemia in patients receiving topical therapy for recurrent herpes simplex (points).




# Analysis of the RF market for antiherpetic drugs, rubles



# Analysis of the RF market for antiherpetic drugs without acyclovir, rubles, indicating the share




# Equity participation of Russian regions in the sales of **ALLOMEDIN®** 2013-2017



## Prerequisites for the development of the **ALLOMEDIN®** brand




More than 10 million Russians each year face the problem of herpes.



Annual increase in the incidence of herpes, including genital.



Consumer dissatisfaction with existing herpes treatments



Growing market for antiherpetic drugs



Distribution of Allomedin® through pharmacies throughout Russia



High awareness of Allomedin® among physicians and pharmacists



**T3  
ALLOMEDIN**



**T3  
ALLOMEDIN**



**T3  
ALLOSTATIN**



**RF patent No.  
2267496 Antiviral  
and antitumor  
peptides**



**Know-how for  
the production  
of Allomedin®  
gel**

**INTELLECTUAL PROPERTIES**

## 5 factors to remember about **ALLOMEDIN®**



Climate Change



Hypothermia



UV Radiation



Stress



Cosmetic procedures

# THANK YOU



## **VAMOS BIOTECH (SHANGHAI) CO., LTD**

2F, Building #5, Lin Gang Fengxian Industrial Park,  
1800 Xin Yang Road, Feng Xian District,  
Shanghai 201413, P.R. China

**Tel:** +86 213 712 3366

**Email:** [info@vamos-biotech.com](mailto:info@vamos-biotech.com)

[www.vamos-biotech.com](http://www.vamos-biotech.com)

